Skip to content

Study · Measured the body's own peptide · 2018

3 results

Unique profile of antimicrobial peptide expression in polymorphic light eruption lesions compared to healthy skin, atopic dermatitis, and psoriasis.

Patra V, Mayer G, Gruber-Wackernagel A, Horn M, Lembo S, Wolf P

Photodermatology, photoimmunology & photomedicine13 Nov 2017Cited by 28 (Europe PMC)

PMID29044786 (opens in a new tab)PMCIDPMC5888155 (opens in a new tab)DOI10.1111/phpp.12355 (opens in a new tab)PepBankPUB-29044786
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundPolymorphic light eruption (PLE) has been attributed to type IV, most likely delayed-type hypersensitivity response (adaptive immunity) but little is known on innate immunity, especially antimicrobial peptides (AMPs) in the disease. Abnormalities in AMP expression have been linked to pathological skin conditions such as atopic dermatitis (AD) and psoriasis.MethodsAntimicrobial peptide profiling was carried out in PLE skin samples (n,12) compared with that of healthy (n,13), atopic (n,6), and psoriatic skin (n,6).ResultsCompared to healthy skin, we observed increased expression of psoriasin and RNAse7 (both mostly in stratum granulosum of the epidermis), HBD-2 (in the cellular infiltrate of the dermis), and LL37 (mostly in and around blood vessels and glands) in PLE lesional skin, a similar expression profile as present in psoriatic skin and different to that of AD (with little or no expression of psoriasin, RNAse7, HBD-2, and LL37). HBD-3 was downregulated in PLE compared to its high expression in the epidermis and dermis of healthy skin, AD, and psoriasis.ConclusionThe unique profile of differentially expressed AMPs in PLE implies a role in the pathophysiology of the disease, possibly directly or indirectly linked to the microbiome of the skin.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    LL37 expression was increased in lesional skin of polymorphic light eruption compared with healthy skin.

    In plain wordsNatural LL‑37 expression was higher in skin lesions of polymorphic light eruption than in healthy skin.

    Peptide
    LL-37
    Outcome
    IncreaseLL37 expression in PLE lesional skin
    Study

    n = 12

    Comparator
    Healthy skin
    Outcome group
    Inflammation markers · Skin and wound

    Source sentences

    Summary
    Compared to healthy skin, we observed increased expression of psoriasin and RNAse7 (both mostly in stratum granulosum of the epidermis), HBD-2 (in the cellular infiltrate of the dermis), and LL37 (mostly in and around blood vessels and glands) in PLE lesional skin
    1 context sentence
    Summary · context
    Antimicrobial peptide profiling was carried out in PLE skin samples (n,12) compared with that of healthy (n,13), atopic (n,6), and psoriatic skin (n,6).

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Psoriatic skin showed an expression profile, including LL37, similar to that in polymorphic light eruption lesions, that is increased versus healthy skin.

    In plain wordsNatural LL‑37 expression in psoriasis skin looked similar to that in light eruption lesions, higher than in healthy skin.

    Peptide
    LL-37
    Outcome
    IncreaseLL37 expression in psoriatic skin
    Study

    n = 6

    Comparator
    Healthy skin
    Outcome group
    Inflammation markers · Skin and wound

    Source sentences

    Summary
    LL37 (mostly in and around blood vessels and glands) in PLE lesional skin, a similar expression profile as present in psoriatic skin
    1 context sentence
    Summary · context
    Antimicrobial peptide profiling was carried out in PLE skin samples (n,12) compared with that of healthy (n,13), atopic (n,6), and psoriatic skin (n,6).

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Atopic dermatitis skin showed little or no LL37 expression, unlike polymorphic light eruption lesions.

    In plain wordsNatural LL‑37 expression in atopic skin was little or none, unlike light eruption lesions.

    Peptide
    LL-37
    Outcome
    DecreaseLL37 expression in atopic dermatitis skin
    Study

    n = 6

    Comparator
    Polymorphic light eruption lesions
    Outcome group
    Inflammation markers · Skin and wound

    Source sentences

    Summary
    different to that of AD (with little or no expression of psoriasin, RNAse7, HBD-2, and LL37).
    1 context sentence
    Summary · context
    Antimicrobial peptide profiling was carried out in PLE skin samples (n,12) compared with that of healthy (n,13), atopic (n,6), and psoriatic skin (n,6).

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.